Stu I from Streptomyces tubercidicus

buffered aqueous glycerol solution

CAS Number:
Enzyme Commission number:
MDL number:
Pricing and availability is not currently available.


buffered aqueous glycerol solution


10,000 units/mL

shipped in

wet ice

storage temp.


Looking for similar products? Visit Product Comparison Guide


Recognition sequence: 5′-AGG/CCT-3′
Ligation and recutting results: After 2-10-fold Stu I overdigestion of 1 μg λ DNA substrate, results in 100% cutting, >90% of fragments can be ligated, and >95% recut.
Heat inactivation: Inactivated at 65 °C for 20 minutes.

Other Notes

Supplied with 10x Restriction Endonuclease Buffer SB (B8781).
Comment: Overlapping dcm methylation will block cleavage by Stu I.

Physical form

Solution in 20 mM Tris-HCl, pH 7.5, 0.1 mM EDTA, 100 mM NaCl, 10 mM 2-mercaptoethanol, 50% glycerol (v/v), 0.01% Triton X-100 (v/v) at 4 °C

WGK Germany


H Shimotsu et al.
Gene, 11(3-4), 219-225 (1980-11-01)
A new sequence-specific endonuclease, StuI, produced by Streptomyces tubercidicus KCC S-0054, was identified and partially purified. StuI recognizes the hexanucleotide "palindromic" sequence (Formula: see text), and cleaves it at the middle, producing blunt ends.
C Kessler et al.
Gene, 92(1-2), 1-248 (1990-08-16)
The properties and sources of all known class-I, class-II and class-III restriction endonucleases (ENases) and DNA modification methyltransferases (MTases) are listed and newly subclassified according to their sequence specificity. In addition, the enzymes are distinguished in a novel manner according...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.